LONIDAMINE IN NON-SMALL-CELL LUNG-CANCER - A PHASE-II STUDY

被引：5

作者：

CONTU, A

OLMEO, NA

PANI, P

DERIU, A

ORTU, S

PAGA, C

机构：

[1] CIVIL HOSP,DEPT MED ONCOL,SASSARI,ITALY

[2] F ANGELINI RES INST,ROME,ITALY

来源：

TUMORI | 1991年 / 77卷 / 01期

关键词：

D O I：

10.1177/030089169107700113

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The activity of lonidamine (a derivative of indazole-carboxylic acid and a new drug with a characteristic antitumor activity) was evaluated in non-small-cell lung cancer (NSCLC). Twenty-five patients with NSCLC with or without prior treatment recieved lonidamine at the dose of 450 mg/daily p.o. up to progression. Objective responses obtained were: 3 (12%) partial responses and 3 (12%) minor responses with a mean duration of 13.7 weeks for partial responses. Mean duration of treatment was 20 weeks (range 4-97+). During to the drug's characteristics, bone marrow toxicity was not observed; myalgia and mild testicular pain were the most significant side effects.

引用

页码：52 / 55

页数：4